Cardlytics (CDLX) director acquires 6,148 shares via RSU vesting
Cardlytics (CDLX) reported an insider equity change by a director.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cardlytics (CDLX) reported an insider equity change by a director. On October 30, 2025, 6,148 restricted stock units converted into 6,148 shares of common stock, shown with transaction code M (conversion of a derivative security) at a stated price of $0, consistent with RSU settlement.
The RSUs were granted on October 30, 2024 and vested in full one year later. After the settlement, the reporting person holds 6,148 shares with direct ownership. No sales were reported in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 6,148 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,148 | $0.00 | $0.00 |
Footnotes (2)
- F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.
- F2. This RSU award was for 6,148 shares with a grant date of October 30, 2024. The RSUs vested in full on the one-year anniversary of the grant date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Cardlytics (CDLX) report?
What was the nature and code of the transaction?
When were the RSUs granted and when did they vest?
What is the reporting person’s ownership after the transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.